Open AccessSafety of nintedanib before lung transplant: an Italian case series
Author(s) -
Balestro Elisabetta,
Solidoro Paolo,
Parigi Piercarlo,
Boffini Massimo,
Lucianetti Alessandro,
Rea Federico
Publication year - 2018
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.312
Subject(s) - nintedanib , medicine , lung transplantation , lung , surgery , idiopathic pulmonary fibrosis , lung function , anastomosis , transplantation
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease that can only be cured by lung transplantation. Pharmacological agents play a role in preserving lung function and prolonging survival until a suitable donor organ becomes available. However, data on the effects of newer antifibrotic therapies on lung transplantation outcomes in IPF patients are lacking. The nine patients included in this case series were treated with nintedanib 150 mg twice daily for 3–30 (mean 13 ± 9) months before lung transplant surgery. In this series, nintedanib preserved lung function up to transplantation, was well tolerated, and had no detrimental effects on the short‐term outcome of lung transplant.